Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 177Neoplasm Metastasis 142Neoplasms 136Leukemia, Myeloid, Acute 128Colorectal Neoplasms 126Breast Neoplasms 115Ovarian Neoplasms 89Melanoma 88Prostatic Neoplasms 86Recurrence 84Multiple Myeloma 81Pancreatic Neoplasms 74Squamous Cell Carcinoma of Head and Neck 72Glioblastoma 72Lung Neoplasms 70Lymphoma, Non-Hodgkin 63Myelodysplastic Syndromes 60Triple Negative Breast Neoplasms 57Glioma 53Stomach Neoplasms 52Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Endometrial Neoplasms 48Carcinoma, Renal Cell 47Small Cell Lung Carcinoma 46Lymphoma, Large B-Cell, Diffuse 44Brain Neoplasms 43Carcinoma, Hepatocellular 41Sarcoma 39Lymphoma, B-Cell 39Advanced Solid Tumors 39

Interventions

pembrolizumab 1omega-N-Methylarginine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × DNA Repair-Deficiency Disorders × 90 days × Clear all
NCT03236935 2026-04-09

Phase Ib of L-NMMA and Pembrolizumab

The Methodist Hospital Research Institute

Phase 1 Completed
12 enrolled 15 charts
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, DNA Repair-Deficiency Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡